1 of 1
Story summary
- Dr. Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s weight-loss drug Wegovy at a price up to 60% lower than the branded product.
- Co-chairman G. V. Prasad stated the company aims to sell 12 million injectable semaglutide pens in the first year after the patent expires in March 2024.
- Dr. Reddy’s has received approval to manufacture a generic version of Ozempic and is awaiting approval for Wegovy.
- The company is pursuing a biosimilar version of the cancer therapy rituximab in the U.S. but will not expand its U.S. manufacturing footprint immediately.
